NEW YORK, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Provista Diagnostics Inc., will be presenting at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York as well as the Evercore ISI MedTools Conference in Boston this month. David E. Reese, PhD Provista’s president and chief executive officer, will present a company update and investor overview on Thursday, November 17 at 2:20 p.m. ET at the Westin Hotel in New York City.
Additionally, Provista Diagnostics has been invited to participate at Evercore ISI’s MedTools Conference at the Boston Harbor Hotel November 30 and December 1.
Provista Diagnostics’ mission is to develop world-class diagnostic tests for breast and gynecologic cancers. Our products aim to help inform better clinical decisions and enhance women’s health and quality of life.
“Over 15 million women are diagnosed each year with either an indeterminate mass or dense breasts which can obscure small cancerous lesions,” stated Dr. Reese. “Provista has developed a new blood-based diagnostic test, Videssa ® Breast, which can help physicians rule out breast cancer and avoid additional diagnostic procedures.”
For more information on the Canaccord MedTech & Diagnostics Forum, check out their website here .
To learn more about Provista Diagnostics, please visit ProvistaDx.com. Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov
About Provista Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
David R. Holmes Provista Diagnostics IR@ProvistaDx.com 212-202-3170
